louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05345431: Endovascular Denervation for the Treatment of Patients With Peripheral Arterial Disease
Official title: Endovascular Denervation for the Treatment of Patients With Peripheral Arterial Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: PAD
Lead sponsor: Zhongda Hospital
Sponsor class: OTHER
First posted: 2022-04-25
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sympathetic overactivity partly promotes the development of peripheral artery disease which mainly leads to ischemia of the lower limbs. Endovascular arterial denervation (ED) is a minimally invasive technique which could deliver Radiofrequency energy by a multi-electrode catheter to the Lower limb artery to restore Sympathetic activity. The purpose of this study is to evaluate the effects of multi-electrode radiofrequency ablation system on lower limb ischemia with PAD.

Detailed description: Peripheral arterial disease(PAD) show insufficient blood supply of diseased limbs, which causes intermittent claudication of lower limbs, reduced skin temperature, pain, and chronic progressive disease that still produces ulcer or necrosis. Some clinical studies have shown Sympathetic overactivity in the lower arterial ischemic disease. The multi-electrode radiofrequency ablation system can significantly reduce the excitability of sympathetic nerve, restore the normal response of sympathetic nerve, relieve the pain and discomfort of patients, effectively improve the symptoms of lower limb ischemia, and improve the quality of life of patients.

Eligibility criteria: Inclusion Criteria:

1. eligible subjects aged 18-75 years,
2. clinically confirmed PAD patients in Rutherford category II-VI.

Exclusion Criteria:

1. thrombolytic therapy performed within 30 days,
2. patients who had undergone vascular bypass surgery before this study,
3. allergy or contraindication of antiplatelet drugs, anticoagulants, thrombolytic drugs and contrast agents,
4. patients with obvious bleeding tendency, coagulation dysfunction, hypercoagulability and blood system diseases,
5. serious liver and kidney diseases,
6. history of hemorrhagic stroke within the last 1 month or ischemic stroke or transient ischemic attack within 2 weeks,
7. pacemaker implants,
8. patients who are pregnant, breast-feeding or planning pregnancy,
9. expected survival \< 24 months.

Primary outcomes:
measure: Ischemia relief
timeFrame: from baseline to 6 months after procedure
Secondary outcomes:
measure: Ischemia relief
timeFrame: from baseline to 3 months after procedure
measure: clinical benefit
timeFrame: from baseline to 3, 6 months after procedure
measure: pain relief
timeFrame: from baseline to 3 ,6 months after procedure
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Zhongda Hospital, Southeast University
state: Jiangsu
Study officials:
affiliation: Zhongda Hospital
name: Gao-Jun Teng, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00335231: Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery
Official title: The Effect of Preoperative Topical Gatifloxacin on Anterior Chamber Sample Cultures After Cataract Surgery.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Endophthalmitis
Keywords: Post-cataract surgery endophthalmitis
Lead sponsor: Queen's University
Sponsor class: OTHER
First posted: 2006-06-09
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Postoperative endophthalmitis, a possible severe complication of cataract surgery, is an infection of the anterior chamber of the eye caused by bacterial contamination and colonization through surgical incisions. Bacteria are thought to originate mainly from the patient's skin and studies show that bacteria are commonly found in the anterior chamber following surgery. However, innate immune defences are usually able to control and eliminate bacterial growth before postoperative endophthalmitis occurs. Also, due to the low incidence of postoperative endophthalmitis, it is difficult to accurately evaluate preventative methods. This study will examine the efficacy of topical preoperative administration of gatifloxacin (a new fourth generation fluoroquinolone antibiotic) on reduction of bacterial contamination of the anterior chamber following cataract surgery. If the antibiotic is shown to lower bacteria count in cultures from anterior chamber fluid, it has the potential to lower the incidence of postoperative endophthalmitis.

Patients undergoing cataract surgery will be notified and asked to participate in the study by the physician in advance of the surgery, provided they do not possess any exclusion criteria. The participants will be randomly split into two groups; one group will receive topical application of gatifloxacin prior to surgery, while the other group will receive no eye drops. During surgery, a small sample of anterior chamber fluid will be removed from the eye and cultured in both broth and enrichment media for all subjects. Bacterial growth, i.e., colony forming units (CFUs), will be used as an indicator of the bacterial contamination of the fluid.


Eligibility criteria: Inclusion Criteria:

* Cataract surgery on first eye (i.e., first cataract surgery.

Exclusion Criteria:

* uveitis,
* herpetic eye disease,
* corneal ulceration,
* severe blepharitis,
* past trauma to the eye,
* complicated cataract surgery (e.g., posterior capsule rupture),
* previous intraocular surgeries.

Primary outcomes:
measure: Difference in bacterial colony forming units (CFUs) between treatment (gatifloxacin) and no treatment group
Secondary outcomes:
measure: Bacterial sensitivity
measure: Patient comfort
Other outcomes:
Locations:
city: Kingston
country: Canada
facility: Hotel Dieu Hospital
state: Ontario
Study officials:
affiliation: Queen's University, Hotel Dieu Hospital, Kingston General Hospital
name: Sherif El-Defrawy, MD PhD FRCSC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02616731: Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD
Official title: Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Menorrhagia
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2015-11-30
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the efficacy of tranexamic acid and diosmin in reducing menstrual blood loss in women having Intra Uterine Contraceptive Device (IUD) and suffer from menorrhagia.


Eligibility criteria: Inclusion Criteria:

* Women complaining from an menorrhagia secondary to a current copper IUD use.
* Age: 20-40years.
* Menorrhagia , will be defined as a PBAC-Score greater than 100.
* No systemic causes of abnormal uterine bleeding as hypertension and hemorrhagic blood diseases.
* No other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis, polyps).
* No drugs decreasing blood coagulation.
* Well fitted IUD not misplaced.

Exclusion Criteria:

* Age \<20y and \>40y.
* Irregular menstrual cycle.
* Presence of systemic causes of abnormal uterine bleeding as hypertension and hemorrhagic blood diseases.
* Presence of other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis, polyps).
* Taking drugs decrease blood coagulation.
* Misplaced IUD.

Primary outcomes:
measure: The amount of reducing heavy menstrual flow will be calculated by the PBAC.
timeFrame: the first 24hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ahmed Alanwar
Study officials:
References:
Clinical trial NCT04285931: Prevelance of Dental Caries in Agroup of Egyption Children Using Caries Assessment Spectrum and Treatment
Official title: Prevelance of Dental Caries in Agroup of Egyption Children Using Caries Assessment Spectrum and Treatment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dental Caries
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-02-26
Enrollment: 250
Sex: ALL
Minimum age (years): 6
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be selected from the Outpatients' clinic of Pediatric Dentistr Department, Faculty of Dentistry, Misr University for Science and Technology

Brief summary: To explore the prevalence of dental caries in Egyptian children aged from 6 to 9 years oldusing CAST index and DMFT index

Detailed description: To explore the prevalence of dental caries in Egyptian children aged from 6 to 9 years oldusing CAST index and DMFT index. from MUST university outpatient clinic

Eligibility criteria: Inclusion Criteria:

* - Parental or guardian acceptance for participation in the study.
* Children who are medically free from any systemic diseases.
* Children with mixed dentition aging from 6-9 years old.
* Both genders.

Exclusion Criteria:

* uncooperative patient

Primary outcomes:
measure: Prevelance of caries using dmft index
timeFrame: 3month
Secondary outcomes:
measure: Prevelance of caries index using cast index
timeFrame: 3 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01483131: Vascular Occlusion in Patients With Osteoarthritis
Official title: Effects of Strength Training Associated With Vascular Occlusion in Patients With Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Osteoarthritis
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2011-12-01
Enrollment: 45
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Resistance exercise plus vascular occlusion may induce greater improvements in strength and muscle mass than resistance training alone. The investigators speculate this training strategy could be beneficial in patients with osteoarthritis.


Eligibility criteria: Inclusion Criteria:

* Postmenopausal women
* BMI \<39
* Knee Ostearthritis type II and III
* VAS (visual analogue scale) between 2 and 8

Exclusion Criteria:

* Hip osteoarthritis
* Use of NSAID

Primary outcomes:
measure: muscle strength
timeFrame: 12 weeks
Secondary outcomes:
measure: Quality of Life
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: University of Sao Paulo -School of Medicine - Clinical Hospital
Study officials:
References:
Clinical trial NCT03819231: Mindfulness Training Plus Oxytocin Effects on Smoking Behavior
Official title: Mindfulness Training Plus Oxytocin to Reduce Smoking and Craving Among Smokers in Withdrawal
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Smoking
Smoking Cessation
Keywords: Mindfulness
Oxytocin
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2019-01-28
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to examine the effects of mindfulness training and a drug called oxytocin on smoking.

Detailed description: Mindfulness training allows individuals to be present with their own emotions, thoughts, and bodily sensations without reactive judgment, and will be given in the form of daily audio recordings. Oxytocin is a naturally occurring hormone in the brain and throughout the body. It is also an FDA-approved drug to help induce labor in pregnant women. In this study, the use oxytocin is experimental and is in the form of a nasal spray.

Eligibility criteria: Inclusion Criteria:

* Smoke at least 10 cigarettes per day for the past year

Exclusion Criteria:

* Current DSM-5 substance use disorder
* Any medial condition that would increase risk for study participation
* Women who are pregnant or nursing
* Current use of psychiatric medication for anxiety or mood disorders
* Planning to quit or reduce smoking in the next 30 days
* Current regular use of other nicotine-containing products
* Current mindfulness or mediation practice of greater than 5 minutes per day

Primary outcomes:
measure: Smoking Lapse Analogue Task (delay score)
timeFrame: 2 hours after nasal spray administration
measure: Trier Social Stress Test
timeFrame: 1 hour after nasal spray administration
Secondary outcomes:
measure: Systolic blood pressure
timeFrame: Throughout study completion, an average of two weeks.
measure: Diastolic blood pressure
timeFrame: Throughout study completion, an average of two weeks.
measure: Heart rate
timeFrame: Throughout study completion, an average of two weeks.
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of Southern California
state: California
Study officials:
affiliation: University of Southern California
name: Matthew Kirkpatrick, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00881673: To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge
Official title: A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge (CAC)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Allergic Conjunctivitis
Keywords: Conjunctivitis
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2009-04-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine whether Al38583 Ophthalmic Solution is safe and effective in reducing tear eosinophil levels at 5-8 hours after Conjunctival Allergen Challenge (CAC).


Eligibility criteria: Inclusion Criteria:

* Have a positive bilateral CAC reaction (\>2 itching and \> conjunctival redness) to cat hair, cat dander, dust mites, cockroaches and/or dog dander within 10 minutes of instillation of the last titration of allergen at Visit 1

Exclusion Criteria:

* Have a known allergy to the study medication(s) or their components (ex., dexamethasone, benzalkonium chloride)

Primary outcomes:
measure: The primary efficacy variable is mean change in tear eosinophil level at Visit 7 post-CAC from Visit 2 post-CAC.
timeFrame: 15 days
Secondary outcomes:
measure: Mean change in relative ratio of tear eosinophil and neutrophils at Visit 7 post-CAC from Visit 2 post-CAC
timeFrame: 15 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06956573: Aortic Dimensions in Patients With Fabry Disease
Official title: Aortic Dimensions in Patients With Fabry Disease
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Fabry Disease
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2025-05-04
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients with Fabry disease

Brief summary: We will conduct a retrospective study aiming to define the characteristics, determinants, and progression of ascending aortic dilatation in adults with Fabry disease, using echocardiography and/or cardiac MRI


Eligibility criteria: Inclusion Criteria: a adult patients with genetically confirmed Fabry disease must be able to signed informed consent for participation in the study

Exclusion Criteria:

Patient refusal to participate in the study

Primary outcomes:
measure: Maximum ascending aortic diameter measured by transthoracic echocardiography or cardiac MRI, expressed as a Z-score.
timeFrame: At baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06973473: Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts:Randomized Comparative Trial.
Official title: Aprospective,Randomized,Comparative Clinical Trial of Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Warts
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2025-05-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: - study population age older than 18years

Brief summary: To assess the clinical efficacy and safety of topical imiquimod 5% cream combined with cryotherapy versus either of theme alone for the treatment of common warts by clinical and dermoscopic assessments.

Detailed description: Topical Imiquimod 5% cream Combined with Cryotherapy Versus either of them alone in Treatment of Common Warts: A prospective Randomized Comparative Trial

Eligibility criteria: Inclusion Criteria:

* Patients with common warts diagnosed clinically and by dermoscopy.
* Patients older than 18years old.

Exclusion Criteria:

* Pregnancy and lactation.
* Immunosuppression or being under any kind of treatment causing
* absolute or relative immunosuppression.
* Patients with chronic systemic diseases.
* All cases of bleeding tendency or using anticoagulants.
* Concurrent use of systemic or topical treatments of warts in the last 4 weeks.

Primary outcomes:
measure: Complete clearance rate of common warts.
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00108173: Brain Reaction to Treatment of Nicotine Dependence
Official title: Neural Substrates of Treatment for Nicotine Dependence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Nicotine Dependence
Keywords: Position Emission Tomography (PET)
Nicotine dependence
functional magnetic resonance imaging
cigarette cues
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2005-04-15
Enrollment: 104
Sex: ALL
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of the study was to determine how the treatments for cigarette craving work.

Hypothesis: During exposure to cigarette-related cues, heavy smokers will have greater reductions in regional brain activation from before to after both forms of active treatments than from before to after placebo.

Detailed description: PET and fMRI scanning were used to examine brain activity and activation in cigarette smokers in response to cigarette-related cues.

Eligibility criteria: Inclusion Criteria:

* Heavy smoker, more than one pack per day
* Free of medical conditions or medications that affect brain activity
* Not pregnant

Exclusion Criteria:

Drug or alcohol dependence Mental Illness Pregnancy Medications that affect brain function Unstable medical conditions

Primary outcomes:
measure: 2-FA PET scan results
timeFrame: Within the first few weeks of study initiation
Secondary outcomes:
Other outcomes:
Locations:
city: West Los Angeles
country: United States
facility: VA Greater Los Angeles Healthcare System, West LA
state: California
Study officials:
affiliation: VA Greater Los Angeles Healthcare System, West LA
name: Arthur L. Brody, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01595373: Local Metabolic Effects of Ghrelin in Skeletal Muscle and Adipose Tissue
Official title: Local Metabolic Effects of Ghrelin: A Clinical Microdialysis Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Healthy
Keywords: Ghrelin
Microdialysis
Controls
Metabolic effects of ghrelin
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2012-05-10
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The metabolic effects of ghrelin is investigated by microdialysis technique. Subjects are healthy young men. End points are interstitial concentrations of glucose, lactate, and glycerol.


Eligibility criteria: Inclusion Criteria:

* healthy male
* age 18-65 years (included)
* Body mass index 20-25 (included)

Exclusion Criteria:

* alcohol abuse
* malignant disease
* use of any medicine except otc painkillers
* any disease recognized
* participation in a trial using radioactive isotopes within the last 6 months

Primary outcomes:
measure: Interstitial concentrations of glycerol
timeFrame: Interstitial concentrations of glycerol at t=120 minutes
Secondary outcomes:
measure: Interstitial concentrations of lactate
timeFrame: Interstitial concentrations of lactate at t=120 minutes
measure: Interstitial concentrations of glucose
timeFrame: Interstitial concentrations of glucose at t=120 minutes
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
Study officials:
affiliation: University of Aarhus
name: Esben T. Vestergaard, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Vestergaard ET, Moller N, Jorgensen JO. Acute peripheral tissue effects of ghrelin on interstitial levels of glucose, glycerol, and lactate: a microdialysis study in healthy human subjects. Am J Physiol Endocrinol Metab. 2013 Jun 15;304(12):E1273-80. doi: 10.1152/ajpendo.00662.2012. Epub 2013 Apr 16.